A20 Controls Macrophage to Elicit Potent Cytotoxic CD4+ T Cell Response

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Wang, Lifeng ^a   Hong, Bangxing ^a   Jiang, Xiaoxia ^a   Jones, Lindsey ^a   Chen, Si Yi ^a   Huang, Xue F ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CELL PROTEIN; GAMMA INTERFERON; GRANZYME B; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN A20; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL ACTIVITY; CELL MATURATION; CONTROLLED STUDY; CYTOTOXICITY; GENE SILENCING; IMMUNOSTIMULATION; INTERFERON PRODUCTION; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DNA-BINDING PROTEINS; GENES, MHC CLASS II; GRANZYMES; INTERFERON-GAMMA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC; UBIQUITIN-PROTEIN LIGASES;

EID: 84868674564     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048930     Document Type: Article

References (39)

1. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, et al. (2010) Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207: 637-650.
2. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, et al. (2010) Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 207: 651-667.
3. Mantovani A, Sica A, Locati M, (2005) Macrophage polarization comes of age. Immunity 23: 344-346.
4. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, et al. (2008) "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med 205: 1261-1268.
5. Gordon S, (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
6. Varin A, Gordon S (2009) Alternative activation of macrophages: Immune function and cellular biology. Immunobiology.
7. Martinez FO, Helming L, Gordon S, (2009) Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 27: 451-483.
8. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, et al. (2004) The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 5: 1052-1060.
9. Lee EG, Boone DL, Chai S, Libby SL, Chien M, et al. (2000) Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289: 2350-2354.
10. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, et al. (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430: 694-699.
11. Song XT, Evel-Kabler K, Shen L, Rollins L, Huang XF, et al. (2008) A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med 14: 258-265.
12. Morelli AE, Larregina AT, Ganster RW, Zahorchak AF, Plowey JM, et al. (2000) Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol 74: 9617-9628.
13. Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, et al. (1996) Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 156: 3678-3686.
14. Esser MT, Haverstick DM, Fuller CL, Gullo CA, Braciale VL, (1998) Ca2+ signaling modulates cytolytic T lymphocyte effector functions. J Exp Med 187: 1057-1067.
15. Shen L, Evel-Kabler K, Strube R, Chen SY, (2004) Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol 22: 1546-1553.
16. Darnell JE Jr, (1997) STATs and gene regulation. Science 277: 1630-1635.
17. Zimmermann A, Trilling M, Wagner M, Wilborn M, Bubic I, et al. (2005) A cytomegaloviral protein reveals a dual role for STAT2 in IFN-{gamma} signaling and antiviral responses. J Exp Med 201: 1543-1553.
18. Man S, Lechler RI, Batchelor JR, Sharrock CE, (1990) Individual variation in the frequency of HLA class II-specific cytotoxic T lymphocyte precursors. Eur J Immunol 20: 847-854.
19. McCarthy SA, Singer A, (1986) Recognition of MHC class I allodeterminants regulates the generation of MHC class II-specific CTL. J Immunol 137: 3087-3092.
20. Echchakir H, Bagot M, Dorothee G, Martinvalet D, Le Gouvello S, et al. (2000) Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol 115: 74-80.
21. Namekawa T, Wagner UG, Goronzy JJ, Weyand CM, (1998) Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum 41: 2108-2116.
22. Norris PJ, Sumaroka M, Brander C, Moffett HF, Boswell SL, et al. (2001) Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones. J Virol 75: 9771-9779.
23. Sun Q, Burton RL, Lucas KG, (2002) Cytokine production and cytolytic mechanism of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures. Blood 99: 3302-3309.
24. Williams NS, Engelhard VH, (1996) Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. J Immunol 156: 153-159.
25. Yasukawa M, Ohminami H, Arai J, Kasahara Y, Ishida Y, et al. (2000) Granule exocytosis, and not the fas/fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4(+) as well as CD8(+) cytotoxic T lymphocytes in humans. Blood 95: 2352-2355.
26. Brown DM, Dilzer AM, Meents DL, Swain SL, (2006) CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol 177: 2888-2898.
27. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, et al. (2005) Primary antitumor immune response mediated by CD4+ T cells. Immunity 22: 371-383.
28. Paludan C, Bickham K, Nikiforow S, Tsang ML, Goodman K, et al. (2002) Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol 169: 1593-1603.
29. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, et al. (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373.
30. Muranski P, Restifo NP, (2009) Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 21: 200-208.
31. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, et al. (1999) CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A 96: 8633-8638.
32. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, et al. (2007) CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109: 5346-5354.
33. Guillot B, Portales P, Thanh AD, Merlet S, Dereure O, et al. (2005) The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment. Br J Dermatol 152: 690-696.
34. Beutner U, MacDonald HR, (1998) TCR-MHC class II interaction is required for peripheral expansion of CD4 cells in a T cell-deficient host. Int Immunol 10: 305-310.
35. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, et al. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358: 2698-2703.
36. Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, et al. (2000) Burkitt lymphoma in the mouse. J Exp Med 192: 1183-1190.
37. Dobrzanski MJ, Reome JB, Hollenbaugh JA, Dutton RW, (2004) Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. J Immunol 172: 1380-1390.
38. Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY, (2006) SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest 116: 90-100.
39. Song XT, Evel-Kabler K, Rollins L, Aldrich M, Gao F, et al. (2006) An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med 3: e11.